Last reviewed · How we verify

SK Bioscience Co., Ltd. — Portfolio Competitive Intelligence Brief

SK Bioscience Co., Ltd. pipeline: 2 marketed, 0 filed, 4 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 4 Phase 3 0 Phase 2 3 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
IXIARO IXIARO marketed
SKYVaricella® SKYVaricella® marketed Live attenuated vaccine Varicella-zoster virus (VZV) Immunology / Infectious Disease
NBP608 (Low Potency) NBP608 (Low Potency) phase 3
GBP510 adjuvanted with AS03 GBP510 adjuvanted with AS03 phase 3 Recombinant protein vaccine Immunology / Infectious Disease
NBP608 (Mid Potency) NBP608 (Mid Potency) phase 3 Corticosteroid Glucocorticoid receptor Dermatology, Immunology, Inflammation
IMOJEV IMOJEV phase 3 Live attenuated vaccine Japanese encephalitis virus Infectious Disease / Immunology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. GlaxoSmithKline · 3 shared drug classes
  2. The University of Hong Kong · 2 shared drug classes
  3. Janssen Research & Development, LLC · 2 shared drug classes
  4. Pfizer · 2 shared drug classes
  5. Sanofi · 2 shared drug classes
  6. University of Oxford · 2 shared drug classes
  7. Aga Khan University · 1 shared drug class
  8. Acrotech Biopharma Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for SK Bioscience Co., Ltd.:

Cite this brief

Drug Landscape (2026). SK Bioscience Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/sk-bioscience-co-ltd. Accessed 2026-05-14.

Related